Abstract | BACKGROUND: Opportunistic fungal infections are a major cause of morbidity and mortality in neutropenic cancer patients and antifungal therapy are used both empirically and therapeutically in these patients. OBJECTIVES: SEARCH STRATEGY: MEDLINE and the Cochrane Library (May 2005). Letters, abstracts and unpublished trials were accepted. Contact to authors and industry. SELECTION CRITERIA: DATA COLLECTION AND ANALYSIS: Data on mortality, invasive fungal infection, colonisation, use of additional (escape) antifungal therapy and adverse effects leading to discontinuation of therapy were extracted by two authors independently. MAIN RESULTS: AUTHORS' CONCLUSIONS:
|
Authors | K J Jørgensen, P C Gøtzsche, H K Johansen |
Journal | The Cochrane database of systematic reviews
(Cochrane Database Syst Rev)
Issue 1
Pg. CD004707
(Jan 25 2006)
ISSN: 1469-493X [Electronic] England |
PMID | 16437492
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
- Antifungal Agents
- Liposomes
- Pyrimidines
- Triazoles
- Amphotericin B
- Fluconazole
- Voriconazole
|
Topics |
- Amphotericin B
(adverse effects, therapeutic use)
- Antifungal Agents
(adverse effects, therapeutic use)
- Aspergillosis
(drug therapy)
- Fluconazole
(adverse effects, therapeutic use)
- Humans
- Liposomes
- Mycoses
(drug therapy)
- Neoplasms
(complications)
- Neutropenia
(drug therapy, microbiology)
- Opportunistic Infections
(drug therapy)
- Pyrimidines
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Triazoles
(adverse effects, therapeutic use)
- Voriconazole
|